Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ITB-MED AB

Home Clinical Trial Sponsors and OrganizationsITB-MED AB

ITB-MED AB

Hagaplan 4, Stockholm, Sweden

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

6 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

100.0%

Trial Status Distribution

Active, not recruiting

6

75.0%

Recruiting

1

12.5%

Suspended

1

12.5%

Clinical Trials

Trials sponsored by this organization (8)

A study to investigate whether treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.

Jul 202412 participants

A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant.

Active, not recruiting

Jan 202446 participants

A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)

Active, not recruiting

Sep 202348 participants

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

Active, not recruiting

Sep 202396 participants

A study to investigate whether treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.

Active, not recruiting

Dec 202112 participants

A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti-thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant.

Active, not recruiting

Dec 202040 participants

A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti-thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant.

Active, not recruiting

Dec 202040 participants

A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)

48 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations